Pfizer v. SpecGx: Xeljanz Patent Suit Dismissed Without Prejudice in 95 Days
Pfizer and affiliated entities sued SpecGx LLC in Delaware over alleged infringement of a reissue patent covering Xeljanz (tofacitinib) 5 mg and 10 mg tablets. The case closed after just 95 days when Pfizer voluntarily dismissed all claims without prejudice under Rule 41 — before SpecGx filed any responsive pleading.
Pfizer’s Pre-Answer Withdrawal Keeps Xeljanz Reissue Patent in Play
On 9 August 2024, Pfizer Inc. together with PF Prism C.V., C.P. Pharmaceuticals International C.V., PBG Puerto Rico LLC, and PF PRISM IMB B.V. filed a patent infringement action against SpecGx LLC in the United States District Court for the District of Delaware (Case No. 1:24-cv-00927). The suit centred on reissue patent USRE041783E and alleged that SpecGx’s proposed generic tofacitinib tablets — marketed as 5 mg and 10 mg equivalents of Pfizer’s Xeljanz — would infringe that patent.
On 12 November 2024, before SpecGx had served an answer or a motion for summary judgment, Pfizer exercised its right under Federal Rule of Civil Procedure 41(a)(1)(A)(i) to dismiss all claims without prejudice by filing a unilateral notice of dismissal. Because no responsive pleading had been served, no court order was required and the dismissal took immediate effect. A without-prejudice dismissal means the underlying patent claims remain intact and the same patent could be reasserted in future proceedings.
The 95-day lifespan is notably short even by the standards of pre-answer pharmaceutical patent cases. The public record does not disclose what prompted the withdrawal — possibilities consistent with this pattern include ongoing licence negotiations, a settlement in principle, a decision to pursue different patent claims, or a strategic reassessment of the ANDA filing timeline. Because the dismissal is without prejudice, practitioners should treat this as a pause rather than a conclusion in the enforcement history of USRE041783E.
Filing to Dismissed without Prejudice in 95 days
95 days — resolved before first responsive pleading, well below median ANDA litigation timeline
Dismissed without prejudice: what the Rule 41 withdrawal means for both parties
Rule 41(a)(1)(A)(i): a unilateral exit before the defendant responds
Under FRCP 41(a)(1)(A)(i), a plaintiff may dismiss an action as of right — without a court order — provided the defendant has not yet served an answer or a motion for summary judgment. Pfizer filed a notice of dismissal at that precise procedural window. The dismissal was self-executing and leaves the court record clean of any merits adjudication on USRE041783E.
No court order requiredWithout prejudice: the patent lives to fight another day
A dismissal without prejudice does not extinguish the underlying patent rights or bar a future infringement action on the same patent against the same or different defendants. Pfizer retains full standing to refile. The public record is silent on whether any side conditions — such as a tolling agreement or licensing arrangement — accompanied this dismissal, so practitioners should not assume finality.
Refiling rights preservedSpecGx escapes judgment — but faces residual patent risk
SpecGx obtained no declaratory judgment, no invalidity ruling, and no finding of non-infringement. The dismissal without prejudice provides no legal shield against a future suit on USRE041783E. SpecGx’s generic tofacitinib programme remains subject to reassertion risk until the reissue patent expires or is separately invalidated.
No declaratory judgment obtainedGeneric tofacitinib market entry remains legally uncertain
The withdrawal without prejudice suggests the competitive dispute over tofacitinib generic entry has not been resolved on the merits. Companies tracking the Xeljanz generic landscape — including potential ANDA filers, formulary managers, and biosimilar strategy teams — should monitor USRE041783E’s enforcement history closely, as refiling or licensing activity could materially affect market entry timing.
Market entry timing unresolvedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Pfizer, Inc. | Company | Global pharmaceutical company — holder of USRE041783E covering tofacitinib (Xeljanz)Search in Eureka ↗ |
| Co-Plaintiff | PF Prism C.V. | Individual | Search in Eureka ↗ |
| Co-Plaintiff | C.P. Pharmaceuticals International C.V. | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Pbg Puerto Rico, LLC | Company | Search in Eureka ↗ |
| Co-Plaintiff | PF Prism Ibm C.V. | Individual | Search in Eureka ↗ |
| Defendant | SpecGx, LLC | Company | SpecGx LLC — specialty generic pharmaceutical manufacturer seeking to market tofacitinib tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | Anne Shea Gaza | Attorney | Counsel for SpecGx, LLCSearch in Eureka ↗ |
| Defendant counsel | Robert M. Vrana | Attorney | Counsel for SpecGx, LLCSearch in Eureka ↗ |
| Defendant law firm | Young Conaway Stargatt & Taylor, LLP | Law Firm | Representing SpecGx, LLCSearch in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) explicitly and confirms that SpecGx had not served an answer or motion for summary judgment at the time of filing. This procedural framing is significant: it means the dismissal is unilateral and self-executing, requiring no judicial approval. Critically, the without-prejudice designation means no claim or issue was adjudicated — USRE041783E’s validity, scope, and enforceability against SpecGx remain entirely open questions under law.
USRE041783E — Tofacitinib (Xeljanz) JAK Inhibitor Formulation Reissue Patent
USRE041783E is a United States reissue patent, corresponding to application number US12/577790. Reissue patents are granted when the patent owner seeks to correct errors in the original grant — including, in many cases, to broaden or clarify claim scope. The underlying technology covers tofacitinib, a JAK (Janus kinase) inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, commercialised by Pfizer as Xeljanz in 5 mg and 10 mg oral tablet formulations.
Reissue patents in the small-molecule pharmaceutical sector are strategically significant because broadened claims can capture generic formulations that might have designed around the original patent. For tofacitinib specifically — a blockbuster with multi-billion dollar annual revenues — the reissue patent represents a key line of defence against generic entry. Any company with an approved or pending ANDA for tofacitinib tablets should treat USRE041783E as a high-priority patent for clearance analysis, particularly given that the dismissal against SpecGx is explicitly without prejudice.
Should your team run an FTO analysis against USRE041783E?
Any company developing, manufacturing, or commercialising generic tofacitinib tablets — or formulating JAK inhibitor products in the same dosage range — should conduct a freedom-to-operate analysis against USRE041783E. This is especially urgent for ANDA filers at Paragraph III or IV certification stages, contract manufacturers supplying tofacitinib API or finished dose, and portfolio teams assessing whether a design-around is feasible given the reissued claim language.
PatSnap Eureka’s FTO Search Agent can map the claim scope of USRE041783E against your product formulation, identify the prosecution history of both the original and reissue proceedings, flag related continuations or divisionals in Pfizer’s tofacitinib portfolio, and surface any inter partes review petitions challenging the patent. This multi-layer analysis gives R&D and IP teams a defensible clearance position before committing to commercial manufacturing.
Run a freedom-to-operate analysis on USRE041783E to assess your product’s exposure
Run FTO in Eureka →Similar JAK Inhibitor & ANDA Patent Cases in Delaware District Court
Cases involving reissue patent assertions over branded small-molecule tablets filed in Delaware District Court, with comparable pre-trial voluntary dismissal patterns.
What this case signals for the JAK inhibitor generic IP landscape
A pre-answer dismissal without prejudice in a branded pharmaceutical patent suit rarely signals the end of enforcement strategy.
Pre-answer dismissals preserve maximum enforcement optionality
When a branded pharmaceutical plaintiff exits before the defendant answers, the patent clock is not running. Pfizer preserves all future enforcement rights against SpecGx and any other ANDA filer targeting tofacitinib. IP teams tracking this space should treat the case closure as a procedural pause, not a commercial clearance.
Reissue patents signal active claim-broadening strategy worth monitoring
USRE041783E is a reissue patent, meaning the claims were reconsidered and potentially broadened after original grant. Reissue patents in ANDA litigation tend to carry stronger offensive posture. Any generic developer in the tofacitinib space should conduct an FTO analysis against the reissued claims specifically — not just the original patent.
Pfizer v SpecGx — key questions answered
The dismissal without prejudice means no court has adjudicated whether SpecGx’s generic tofacitinib infringes USRE041783E. Pfizer retains the right to refile the same claims against SpecGx at any time. Generic market entry remains legally uncertain until the patent expires, is invalidated in separate proceedings, or a licence is granted.
Rule 41(a)(1)(A)(i) allows a plaintiff to dismiss unilaterally before the defendant serves an answer or summary judgment motion. Pfizer’s use of this provision suggests a strategic preference to exit without a court order — consistent with ongoing negotiations, a change in enforcement priorities, or a decision to refile on different grounds. The public record does not disclose the specific rationale.
USRE041783E is a reissue of a US patent covering tofacitinib formulations, corresponding to application US12/577790. Reissue patents can carry broadened claims relative to the original grant, making them a potent tool in ANDA litigation. For Xeljanz, a multi-billion dollar product, this patent represents a significant barrier to generic entry that ANDA filers must clear or design around.
The dismissal without prejudice provides no legal clearance for SpecGx to launch. SpecGx obtained no ruling on non-infringement or invalidity. Pfizer could refile suit on USRE041783E, and SpecGx’s launch would remain subject to potential injunctive relief. Separately, Orange Book patent listings and FDA approval timelines govern when SpecGx may commercially launch.
Pfizer and its co-plaintiffs were represented by Morris, Nichols, Arsht & Tunnell LLP, with attorneys Jack B. Blumenfeld and Megan Elizabeth Dellinger listed. SpecGx was represented by Young Conaway Stargatt & Taylor, LLP, with attorneys Anne Shea Gaza and Robert M. Vrana listed. Both firms are leading Delaware patent litigation practices.
PatSnap Eureka searches patents and litigation data to answer instantly.